Mackenzie Financial
SRPT icon

Mackenzie Financial’s Sarepta Therapeutics SRPT Stock Holding History

Mackenzie Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
599,576
+543,444
+968% +$10.3M 0.01% 612
2026
Q1 		$1.22M Sell
56,132
-1,910
-3% -$37K ﹤0.01% 1042
2025
Q4 		$1.24M Buy
58,042
+8,494
+17% +$179K ﹤0.01% 996
2025
Q3 		$955K Buy
49,548
+20,616
+71% +$368K ﹤0.01% 1079
2025
Q2 		$495K Buy
28,932
+8,751
+43% +$373K ﹤0.01% 1231
2025
Q1 		$1.29M Sell
20,181
-3,081
-13% -$324K ﹤0.01% 909
2024
Q4 		$2.83M Sell
23,262
-9,238
-28% -$1.13M ﹤0.01% 679
2024
Q3 		$4.06M Sell
32,500
-28,761
-47% -$3.98M 0.01% 583
2024
Q2 		$9.68M Buy
61,261
+24,836
+68% +$3.19M 0.01% 435
2024
Q1 		$4.72M Buy
36,425
+26,216
+257% +$3.21M 0.01% 565
2023
Q4 		$984K Sell
10,209
-10,308
-50% -$989K ﹤0.01% 870
2023
Q3 		$2.47M Sell
20,517
-12,330
-38% -$1.39M ﹤0.01% 668
2023
Q2 		$3.73M Sell
32,847
-7,935
-19% -$1.02M 0.01% 615
2023
Q1 		$5.62M Sell
40,782
-4,195
-9% -$544K 0.01% 527
2022
Q4 		$5.83M Buy
44,977
+3,831
+9% +$444K 0.01% 498
2022
Q3 		$4.55M Buy
41,146
+37,393
+996% +$3.77M 0.01% 545
2022
Q2 		$281K Buy
+3,753
New +$276K ﹤0.01% 1122
2021
Q1 		– Sell
-6,755
Closed -$1.15M – 1194
2020
Q4 		$1.15M Sell
6,755
-2,996
-31% -$444K ﹤0.01% 695
2020
Q3 		$1.37M Sell
9,751
-5,018
-34% -$763K ﹤0.01% 620
2020
Q2 		$2.37M Buy
+14,769
New +$2.01M 0.01% 518
2019
Q2 		– Sell
-2,412
Closed -$287K – 1236
2019
Q1 		$287K Sell
2,412
-1,703
-41% -$219K ﹤0.01% 1115
2018
Q4 		$449K Buy
4,115
+560
+16% +$70K ﹤0.01% 957
2018
Q3 		$574K Buy
+3,555
New +$486K ﹤0.01% 853

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mackenzie Financial's SRPT Position: Q2 2026 in Review

Mackenzie Financial increased its Sarepta Therapeutics (SRPT) stake by 968% in Q2 2026, buying an estimated $10.3M and bringing the position to 599,576 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #612.

Mackenzie Financial first reported a position in SRPT in Q3 2018 and has held it in 23 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Mackenzie Financial held 599,576 shares of Sarepta Therapeutics worth $10.8M as of Q2 2026.
  • Mackenzie Financial bought 543,444 Sarepta Therapeutics shares in Q2 2026, an estimated $10.3M.
  • Sarepta Therapeutics made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #612 holding.
  • Mackenzie Financial first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 23 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.